Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors

Journal of Neuro-Oncology

Volumn 70, Issue 1, 2004, Pages 23-28

  Lesniak, Maciej S ^a,b   Gabikian, Patrick ^c   Tyler, Betty M ^c   Pardoll, Drew M ^b   Brem, Henry ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Brain tumors; Dexamethasone; Histopathology; Immunohistochemistry; Immunotherapy; Interleukins; Steroids

Indexed keywords

CD8 ANTIGEN; DEXAMETHASONE; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MELANOMA CELL; MOUSE; MOUSE STRAIN; NONHUMAN; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; WILD TYPE;

ANIMALS; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GLUCOCORTICOIDS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RATS; SKIN NEOPLASMS; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS;

EID: 4444350998     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000040821.50347.c5     Document Type: Article

References (23)

1. Ewend MG, Thompson RC, Anderson R, Sills AK, Staveley-O'Carroll K, Tyler BM et al.: Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. J Immunother 23(4): 438-448, 2000
2. Deshmukh P, Glick RP, Lichtor T, Moser R, Cohen EP: Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice. J Neurosurg 94(2): 287-292, 2001
3. Glick RP, Lichtor T, de Zoeten E, Deshmukh P, Cohen EP: Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery 45(4): 867-874, 1999
4. Hanes J, Sills A, Zhao Z, Suh KW, Tyler B, DiMeco F et al.: Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 18(7): 899-906, 2001
5. Lesniak M, Sampath P, DiMeco F, Viglione M, Pardoll DM, Tyler B et al.: Comparative analysis of paracrine immunotherapy in experimental brain tumors. Neurosurgical Focus 9(6)(4), 2000
6. Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP: Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 9(5): 464-469, 2002
7. Sampath P, Hanes J, DiMeco F, Tyler BM, Brat D, Pardoll DM et al.: Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res 59(9): 2107-2114, 1999
8. Thompson RC, Pardoll DM, Jaffee EM, Ewend MG, Thomas MC, Tyler BM et al.: Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J Immunother Emphasis Tumor Immunol 19(6): 405-413, 1996
9. Lesniak MS, Tyler BM, Pardoll DM, Brem H: Gene therapy for experimental brain tumors using a xenogenic cell line engineered to secrete hIL-2. J Neurooncol 64(1-2): 155-160, 2003
10. Hu X, Li WP, Meng C, Ivashkiv LB: Inhibition of IFN-gamma signaling by glucocorticoids. J Immunol 170(9): 4833-4839, 2003
11. Pipitone N, Sinha M, Theodoridis E, Goulding N, Hall M, Lanchbury J et al.: The glucocorticoid inhibition of LFA-1 and CD2 expression by human mononuclear cells is reversed by IL-2, IL-7 and IL-15. Eur J Immunol 31(7): 2135-2142, 2001
12. Dranoff G, Jaffee EM, Lazenby A, Golumbek P, Levitsky H, Brose K et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte colony macrophage stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-1543, 1993
13. Kaplan EL, Meier P: Nonparametric estimation from nonparametric observation. J Am Stat Assoc 53: 457-481, 1987
14. Brunetti M MN, Colasante A: Spontaneous and glucocorticoid-induced apoptosis in human mature T lymphocytes. Blood 86: 4199-4205, 1995
15. Cupps TR FA: Corticosteroid-mediated immunoregulation in man. Immunol Rev 65: 133-155, 1982
16. Schmidt M PH, Lugering N: Glucocorticoids induce apoptosis in human monocytes: potential role of IL-1 beta. J Immunol 163: 3484-3490, 1999
17. Neuwelt EA KK, Hill S: Immune responses in patients with braintumors. Factors such as anti-convulsants that may contribute to impaired cell-mediated imunity. Cancer 51: 248-255, 1983
18. Badie B, Schartner JM, Paul J, Bartley BA, Vorpahl J, Preston JK: Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg 93(4): 634-639, 2000
19. Aloisi F: Immune function of microglia. Glia 36(2): 165-179, 2001
20. Aloisi F, Ria F, Penna G, Adorini L. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J Immunol 160(10): 4671-4680, 1998
21. Owens T, Babcock A: Immune response induction in the central nervous system. Front Biosci 7: d427-438, 2002
22. Olson JK, Girvin AM, Miller SD: Direct activation of innate and antigen-presenting functions of microglia following infection with Theiler's virus. J Virol 75(20): 9780-9789, 2001
23. Drew PD, Chavis JA: Inhibition of microglial cell activation by cortisol. Brain Res Bull 52(5): 391-396, 2000